Last update 23 Jan 2025

albumin x CLDN18.2 x CD3

Basic Info

Related Targets
albuminCLDN18.2CD3

Related

2
Drugs associated with albumin x CLDN18.2 x CD3
DR30318
Target
CD3 x CLDN18.2 x albumin
Mechanism
CD3 stimulants [+2]
Active Org.
Zhejiang Doer Biologics Co., Ltd.Zhejiang Doer Biologics Co., Ltd.
Originator Org.
Zhejiang Doer Biologics Co., Ltd.Zhejiang Doer Biologics Co., Ltd.
Active Indication
Solid tumor
Inactive Indication-
Drug Highest PhaseIND Application
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
DR-30310
Target
CD3 x CLDN18.2 x albumin
Mechanism
CD3 inhibitors [+2]
Active Org.
Zhejiang Doer Biologics Co., Ltd.Zhejiang Doer Biologics Co., Ltd.
Originator Org.
Zhejiang Doer Biologics Co., Ltd.Zhejiang Doer Biologics Co., Ltd.
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
100 Clinical Results associated with albumin x CLDN18.2 x CD3
Login to view more data
100 Translational Medicine associated with albumin x CLDN18.2 x CD3
Login to view more data
0 Patents (Medical) associated with albumin x CLDN18.2 x CD3
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free